Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EKF Diagnostics Holdings plc (EKDHF)
Cardiff, GB
EKF Diagnostics Holdings plc, a company founded in Cardiff, United Kingdom in 1990, specializes in the global design, development, manufacture, and sale of diagnostic instruments, reagents, and supporting products. Operating across Europe, the Middle East, the Americas, Asia, and Africa, the company offers a comprehensive range of solutions for clinical diagnostics. Their product line encompasses various diagnostic tools, including hemoglobin analyzers such as the hand-held DiaSpect Tm, DiaSpect Hemoglobin T, and the lab-quality Hemo Control, alongside the HemataStat II microhematocrit centrifuge. For diabetes management and monitoring, EKF provides glycated hemoglobin analyzers like Quo-Lab A1c and Quo-Test A1c, in addition to glucose and lactate analyzers such as the Biosen C-Line GP+, C-Line Clinic, and Lactate Scout 4. The company also manufactures specialized analyzers, including the STAT-Site M Beta-hydroxybutyrate analyzer, Creamatocrit Plus for assessing lipid concentration and calorific density in mothers' milk, and pregnancy tests like QuPID and True20. EKF's portfolio extends to clinical chemical analyzers and reagents covering ketosis monitoring (Beta-hydroxybutyrate, Nitro-tab Ketone tablets), Glycated Albumin, Glycated Serum Protein, and Procalcitonin, a marker for bacterial infection and sepsis. Additional offerings include RaPET Serology immunoassay kits, rapid tests like QuStick Strep A for Strep A infections, and various laboratory instruments such as the Altair 240 chemistry analyzer, Excel semi-automated chemistry analyzer, and Micro 12 centrifuge. EKF also supplies Hema-Screen Serology for early colorectal cancer detection, the Uri-Trak 120 urine analyzer, and provides kits and services related to COVID-19. Beyond product sales, the company offers contract manufacturing solutions to third-party businesses and provides laboratory services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.77% | +8.41% | +2.08% | -13.28% | +1.10% | +9.92% | +6.74% | -49.60% | +141.14% | -19.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Devices: +11.2%+2.7% Q4'25: +2.3% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%-65.9% Q4'25: -93.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+3.0% Q4'25: +14.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+13.1% ★ Q4'25: +12.0% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+7.3% ★ Q4'25: +13.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-1.2% ★ Q4'25: -1.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.21× ★ Q4'25: 0.05× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30.05M
est: 67.65M (-55.6%)
|
38.59M
est: 47.08M (-18.0%)
|
41.58M
est: 55.95M (-25.7%)
|
42.54M
est: 54.75M (-22.3%)
|
44.92M
est: 60.43M (-25.7%)
|
65.26M
est: 88.37M (-26.2%)
|
81.84M
est: 99.75M (-18.0%)
|
66.64M
est: 79.76M (-16.5%)
|
52.61M
est: 67.89M (-22.5%)
|
50.19M
est: 50.20M (0.0%)
|
51.56M
est: 51.59M (-0.1%)
|
54.49M
54.37M – 54.64M
+5.6% YoY
|
58.24M
57.96M – 58.79M
+6.9% YoY
|
61.70M
61.48M – 62.08M
+5.9% YoY
|
65.22M
64.99M – 65.62M
+5.7% YoY
|
| EBITDA |
-7.35M
est: 17.16M (-142.8%)
|
4.46M
est: 11.94M (-62.6%)
|
8.43M
est: 14.19M (-40.6%)
|
16.19M
est: 13.89M (+16.6%)
|
10.02M
est: 15.33M (-34.7%)
|
20.04M
est: 22.42M (-10.6%)
|
27.39M
est: 25.30M (+8.2%)
|
-2.18M
est: 15.53M (-114.1%)
|
7.68M
est: 13.21M (-41.9%)
|
11.16M
est: 8.04M (+38.7%)
|
6.74M
est: 8.26M (-18.4%)
|
8.73M
8.71M – 8.75M
+5.6% YoY
|
9.33M
9.29M – 9.42M
+6.9% YoY
|
9.88M
9.85M – 9.94M
+5.9% YoY
|
10.45M
10.41M – 10.51M
+5.7% YoY
|
| EBIT |
-15.40M
est: 11.13M (-238.3%)
|
-498.0K
est: 7.75M (-106.4%)
|
4.41M
est: 9.21M (-52.1%)
|
12.20M
est: 9.01M (+35.4%)
|
5.58M
est: 9.95M (-43.9%)
|
15.43M
est: 14.54M (+6.1%)
|
21.50M
est: 16.42M (+31.0%)
|
-8.84M
est: 8.42M (-205.0%)
|
2.21M
est: 7.17M (-69.2%)
|
6.43M
est: 4.33M (+48.7%)
|
6.74M
est: 4.45M (+51.7%)
|
4.70M
4.69M – 4.71M
+5.6% YoY
|
5.02M
5.00M – 5.07M
+6.9% YoY
|
5.32M
5.30M – 5.35M
+5.9% YoY
|
5.62M
5.60M – 5.66M
+5.7% YoY
|
| Net Income |
-37.12M
est: 4.88M (-860.5%)
|
-18.0K
est: 2.34M (-100.8%)
|
2.72M
est: 4.31M (-37.1%)
|
10.11M
est: 6.76M (+49.6%)
|
3.68M
est: 8.69M (-57.7%)
|
11.11M
est: 22.99M (-51.7%)
|
15.85M
est: 23.06M (-31.3%)
|
-9.58M
est: 10.13M (-194.5%)
|
2.35M
est: 4.07M (-42.2%)
|
6.24M
est: 4.98M (+25.4%)
|
2.12M
est: 6.54M (-67.6%)
|
7.36M
7.32M – 7.42M
+12.4% YoY
|
8.28M
8.24M – 8.35M
+12.5% YoY
|
9.20M
9.16M – 9.27M
+11.1% YoY
|
10.73M
10.68M – 10.82M
+16.7% YoY
|
| SGA |
29.16M
est: 17.09M (+70.6%)
|
18.73M
est: 11.89M (+57.5%)
|
18.19M
est: 14.14M (+28.6%)
|
10.59M
est: 13.83M (-23.5%)
|
18.28M
est: 15.27M (+19.7%)
|
20.66M
est: 22.33M (-7.5%)
|
17.71M
est: 25.20M (-29.7%)
|
23.18M
est: 20.70M (+12.0%)
|
17.88M
est: 17.62M (+1.5%)
|
13.68M
est: 15.01M (-8.9%)
|
16.43M
est: 15.43M (+6.5%)
|
16.30M
16.26M – 16.34M
+5.6% YoY
|
17.42M
17.33M – 17.58M
+6.9% YoY
|
18.45M
18.38M – 18.56M
+5.9% YoY
|
19.50M
19.43M – 19.62M
+5.7% YoY
|
| EPS |
-0.09
est: 0.01 (-918.7%)
|
0.00
est: 0.01 (-100.8%)
|
0.01
est: 0.01 (-37.9%)
|
0.02
est: 0.01 (+48.5%)
|
0.01
est: 0.02 (-57.7%)
|
0.02
est: 0.05 (-51.8%)
|
0.03
est: 0.05 (-31.7%)
|
-0.02
est: 0.02 (-193.7%)
|
0.01
est: 0.01 (-42.1%)
|
0.01
est: 0.01 (+24.3%)
|
0.00
est: 0.01 (-67.8%)
|
0.02
0.02 – 0.02
+12.4% YoY
|
0.02
0.02 – 0.02
+12.5% YoY
|
0.02
0.02 – 0.02
+11.1% YoY
|
0.02
0.02 – 0.02
+16.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Helen Mary Kinsey Jones | Chief Financial Officer & Director | 381.5K | female |
| Julian Huw Baines | Executive Chairman | 350.1K | male |
| Gavin Joseph Jones | Chief Executive Officer & Director | 314.7K | male |
| Stephen Young | Chief Financial Officer & Executive Director | 303.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EKDHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
